A. Borgman-Hagey

Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).

J. Furuse, G. Abou-Alfa, R. Kelley, 2014 .

Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2019, Annals of Oncology.

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

G. Abou-Alfa, R. Kelley, A. El-Khoueiry, 2018 .

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

P. Kantoff, T. Powles, R. Motzer, 2015, The New England journal of medicine.

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Gisela Schwab, Tim Meyer, Stephen Lam Chan, 2018, The New England journal of medicine.

Cabozantinib in Hepatocellular Carcinoma.

G. Abou-Alfa, R. Kelley, A. Borgman-Hagey, 2018, The New England journal of medicine.

742TiPPHASE 3 RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS PLACEBO IN SUBJECTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED PRIOR SORAFENIB (CELESTIAL) (NCT01908426).

M. Colombo, J. Furuse, G. Abou-Alfa, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.